Curcumin

Curcumin has been studied in 724 papers since 1998: 201 trials and 6 observational studies in people, 93 in animals, 34 in cells, 381 reviews; 113 in the past year. The newest story, Oct 28, 2026: “Food colorings linked to higher cardiovascular disease risk”.

Intervention

724 papers study it66 more mention it697 findingsUpdated

PubChemChEBIMeSH

Research on it is growing about as fast as aging research as a whole: 44 papers in the latest year counted

More supplements

12 new papers in 30 daysSee all 566 papers on curcumin

At a glance

Independent labs report longer worm lifespan and reduced human inflammation with curcumin, although other human results show no clear inflammatory effect. Human trials report both improved flow-mediated dilation and no clear effect. Registrations include one aging-related trial; across uses, 31 trials ended over a year ago without posted results; some papers declare company ties.

697 findings in 280 papers from 2001 to 2026, 20 of them since April 2026

Independent labs found the same change in cells, worms or flies, mice and people. 157 independent labs in 39 countries; 110 trials, 1 about aging, 31 with no results posted.

“curcumin-treated group showed a significant decrease in fasting blood glucose (115.49 vs.130.71; P < 0.05), HbA1c (6.12 vs. 6.47; P < 0.05)”
Curcumin extract improves beta cell functions in obese patients with type 2 diabetes: a randomized controlled trialNutrition journal2024doi:10.1186/s12937-024-01022-3

89 of its findings point the other way.

Cells, worms or flies, mice and humans: replicated by independent labs.
  • 157 independent labs in 39 countries
  • 89 findings against
  • 110 trials, 1 about aging, 31 with no results posted
  • Funders: National Institutes of Health and others
  • 35 of 667 findings with company ties
  • Human trial94
  • Humans6
  • Animals66
  • Model organisms22
  • Cells30
  • In silico4

78 studies gave curcumin to people and measured what changed.

What changedDesignPeopleSource

down: Decreases HbA1c

Review of trials113,122 people pooledadultsAdult patients with prediabetesClinical and translational medicine, Sep 1, 2026

no change: Has no effect on retinal thickness

no change: Has no effect on logMAR-corrected distance visual acuityMD 0.08, 95% CI -0.04 to 0.20; P = 0.12

down: Decreases HbA1cGreater reduction: MD 0.63%, 95% CI 0.3–1.0; P < 0.001

Randomized trial3 months52 peopleDiabetic macular edema; adjunct to intravitreal bevacizumab versus matched placeboInternational journal of retina and vitreous, Aug 3, 2026

no change: Has no effect on homocysteineSMD -2.08, 95% CI -4.67 to 0.51

Review of trials110 people pooledMeta-analysis of two RCTsFrontiers in pharmacology, Jul 16, 2026

no change: Has no effect on pain

no change: Has no effect on physical function

down: Decreases pain-1.74 ± 0.73

Randomized trialthree months27 people24 patients (88%) were femaleaged over 50 yearsPatients aged over 50 years, diagnosed with hand osteoarthritis according to the American College of Rheumatology criteria for the conditionBMC complementary medicine and therapies, Oct 6, 2025

up: Improves musculoskeletal healthMD: 5.3; 95% CI: 3.3 to 7.4

down: Decreases fatigueMD: −2.6; 95% CI: −3.8 to −1.4

no change: Has no effect on depression

Randomized trial8 weeks74 peoplewomenaged 40–60 yearsPostmenopausal women referred to the Sheikh Al Rais Clinic and Psychiatry Clinic of Imam Reza in Tabriz City-IranBMJ open, Sep 21, 2025

What did mouse lifespan tests of curcumin find?

NIA ITP

The NIA Interventions Testing Program ran 1 arm in 2007; the change in median lifespan ran from +3% to +5%.

What did other lifespan studies of curcumin find?

DrugAge

DrugAge records 35 results from 10 papers: 31 in D. melanogaster and 4 in C. elegans. Average lifespan is the mean or the median, as each paper reports it.

What did studies of curcumin find?

332

Studies of curcumin measured 332 outcomes; the most studied are inflammation (25 studies), oxidative stress and ROS signaling (23) and lifespan (20).

Inflammation

downin humans11downin reviews8downin mice2downin human cells1+3

25 studies
  1. Curcumin decreases inflammation in humans with diabetes and atherosclerotic cardiovascular risk.

    “TNF-α levels significantly declined overtime (P < 0.001) only in the curcumin group and were significantly lower (P = 0.044) versus controls at the end of the study.”

    Human trialwith diabetes and atherosclerotic cardiovascular risk14 weeksn = 72

    Curcumin supplementation improves the clinical outcomes of patients with diabetes and atherosclerotic cardiovascular risk

    Scientific reports

  2. Curcumin showed no clear effect on inflammation in humans.

    “The results showed no significant changes in C-reactive protein (CRP), interleukin-6 (IL-6), tumor necrosis factor α (TNF-α), interleukin-1 β (IL-1β), or blood morphology due to curcumin supplementation.”

    Human trial2g/day6-weekn = 30

    Does curcumin supplementation affect inflammation, blood count and serum brain-derived neurotropic factor concentration in amateur long-distance runners?

    PloS one

  3. Curcumin decreases inflammation in humans during treadmill stress testing.

    “NaC supplementation in overweight/preobese women improved systemic inflammation during treadmill stress testing.”

    Human trialduring treadmill stress testingnanocurcumin80 mg daily8 weeksfemalesn = 48

    Influence of 8 Weeks of Tabata High-Intensity Interval Training and Nanocurcumin Supplementation on Inflammation and Cardiorespiratory Health among Overweight Elderly Women

    Preventive nutrition and food science

  4. Curcumin decreases inflammation in humans (chronic kidney disease).

    “Curcumin significantly reduced plasma pro-inflammatory mediators (CCL-2, IFN-γ, and IL-4)”

    Human trialchronic kidney disease6 monthsn = 24

    Curcumin Supplementation (Meriva®) Modulates Inflammation, Lipid Peroxidation and Gut Microbiota Composition in Chronic Kidney Disease

    Nutrients

  5. Curcumin decreases inflammation in humans.

    “high-sensitivity C-reactive protein (hs- CRP), Interleukin 1 beta (IL-1β) and tumor necrosis factor-alpha (TNF-α) in comparison to the placebo (p<0.05)”

    Human trialnanomicelle and conventional formulations8 weeksn = 90

    Curcumin Nanomicelle Improves Lipid Profile, Stress Oxidative Factors and Inflammatory Markers in Patients Undergoing Coronary Elective Angioplasty; A Randomized Clinical Trial

    Endocrine, metabolic & immune disorders drug targets

  6. Curcumin decreases inflammation (metabolic syndrome).

    “Experimental evidence suggests that curcumin can reduce inflammation and oxidative stress, regulate adipokines, improve lipid metabolism, and support vascular health.”

    Reviewmetabolic syndrome

    Curcumin and metabolic syndrome: Mechanistic and clinical evidence for modulating diabetes and cardiovascular risk factors

    Current research in pharmacology and drug discovery

  7. Curcumin decreases inflammation.

    “Its biological effects are attributed to potent anti-inflammatory and antioxidant properties”

    Review

    Anti-aging activity of curcumin: an old acquaintance with a new face

    Problems of ageing and longevity (Ukraine)

  8. Curcumin decreases inflammation in specific clinical contexts.

    “curcumin demonstrates anti-inflammatory and cardiometabolic effects in specific clinical contexts”

    Reviewin specific clinical contexts

    Research Synthesis: Curcumin Inflammaging — full paper

    Preprint

  9. Curcumin decreases inflammation in inflammatory models.

    “suppress TLR signaling”

    Reviewin inflammatory models

    Modulation of Toll-like Receptors with Natural Compounds: A Therapeutic Avenue Against Inflammaging?

    International journal of molecular sciences

  10. Curcumin decreases inflammation in prediabetes and diabetes (SMD: - 0.50).

    “Curcumin/turmeric supplementation significantly reduced CRP (SMD: - 0.50), TNF-α (SMD: - 1.70), IL-6 (SMD: - 2.97), and MDA (SMD: - 1.31)”

    Reviewin prediabetes and diabetes

    Efficacy of curcumin/turmeric on inflammation and oxidative stress in prediabetes and type 2 diabetes: a systematic review and dose-response meta-analysis

    Inflammopharmacology

All 26

More on Inflammation

Oxidative stress and ROS signaling

downin humans7downin flies3downin mice3downin reviews3+3

23 studies
  1. Curcumin decreases oxidative stress and ROS signaling in humans (chronic kidney disease).

    “Curcumin significantly reduced plasma pro-inflammatory mediators (CCL-2, IFN-γ, and IL-4) and lipid peroxidation.”

    Human trialchronic kidney disease6 monthsn = 24

    Curcumin Supplementation (Meriva®) Modulates Inflammation, Lipid Peroxidation and Gut Microbiota Composition in Chronic Kidney Disease

    Nutrients

  2. Curcumin decreases oxidative stress and ROS signaling in humans.

    “Curcumin and nano-curcumin supplementation also exhibited significant changes in plasma levels of total antioxidant capacity (TAC), malondialdehyde (MDA)”

    Human trialnanomicelle and conventional formulations8 weeksn = 90

    Curcumin Nanomicelle Improves Lipid Profile, Stress Oxidative Factors and Inflammatory Markers in Patients Undergoing Coronary Elective Angioplasty; A Randomized Clinical Trial

    Endocrine, metabolic & immune disorders drug targets

  3. Curcumin decreases oxidative stress and ROS signaling in patients with diabetes on hemodialysis (β = -0.25 μmol/L, 95% CI: -0.45 to -0.04).

    “and plasma malondialdehyde (β = -0.25 μmol/L, 95% CI: -0.45 to -0.04; P < .05)”

    Human trialin patients with diabetes on hemodialysis80 mg/d12 weeksn = 60

    The Effects of Nano-curcumin on Metabolic Status in Patients With Diabetes on Hemodialysis, a Randomized, Double Blind, Placebo-controlled Trial

    Iranian journal of kidney diseases

  4. Curcumin decreases oxidative stress and ROS signaling (metabolic syndrome).

    “Experimental evidence suggests that curcumin can reduce inflammation and oxidative stress, regulate adipokines, improve lipid metabolism, and support vascular health.”

    Reviewmetabolic syndrome

    Curcumin and metabolic syndrome: Mechanistic and clinical evidence for modulating diabetes and cardiovascular risk factors

    Current research in pharmacology and drug discovery

  5. Curcumin decreases oxidative stress and ROS signaling in ageing and diabetic populations.

    “Furthermore, we examine emerging micronutrients and their potential therapeutic benefits, such as Magnesium, Folic Acid, and Curcumin, in reducing oxidative stress and modulating immune function.”

    Reviewin ageing and diabetic populations

    Micronutrients in immune ageing and diabetic wound healing: modulating inflammation and promoting tissue repair

    Acta diabetologica

  6. Curcumin decreases oxidative stress and ROS signaling in a comorbid AD and GU rat model.

    “reduced oxidative stress and inflammation”

    Animalsin a comorbid AD and GU rat modelmales

    Dual protective role of curcumin- encapsulated chitosan nanoparticles against gastric and neural injury in a rat model of gut-brain axis dysfunction: a histological and biochemical study

    Naunyn-Schmiedeberg's archives of pharmacology

  7. Curcumin decreases oxidative stress and ROS signaling in streptozotocin-induced diabetic rats.

    “decreasing oxidative stress markers (MDA)”

    Animalsin streptozotocin-induced diabetic ratsbrainmales

    Neurotherapeutic Efficacy of Nano-curcumin or Nano-chromium Against Streptozotocin-induced Diabetic Neuropathy via Modulation of Oxidative Stress, Pyroptosis, Tau Deposition, miR-223-3p and miR-124

    Microscopy and microanalysis : the official journal of Microscopy Society of America, Microbeam Analysis Society, Microscopical Society of Canada

  8. Curcumin decreases oxidative stress and ROS signaling in prediabetes and diabetes (SMD: - 1.31).

    “MDA (SMD: - 1.31), while significantly increasing GSH (SMD: 1.72) and TAC (SMD: 1.03)”

    Reviewin prediabetes and diabetes

    Efficacy of curcumin/turmeric on inflammation and oxidative stress in prediabetes and type 2 diabetes: a systematic review and dose-response meta-analysis

    Inflammopharmacology

  9. Curcumin inhibits oxidative stress and ROS signaling in humans.

    “curcumin supplementation can modify FBS and some glycemic indices, lipid parameters, as well as inflammatory and oxidative parameters.”

    Reviewn = 7,216

    Curcumin on Human Health: A Comprehensive Systematic Review and Meta-Analysis of 103 Randomized Controlled Trials

    Phytotherapy research : PTR

  10. Curcumin decreases oxidative stress and ROS signaling in adult life stage-specific Drosophila model of Parkinson's disease.

    “K can sequester the enhanced levels of brain oxidative stress (OS) during both adult life phases i.e. health and transition stages”

    Model organismsin adult life stage-specific Drosophila model of Parkinson's diseasebrain

    Sequestration of oxidative is necessary but not sufficient enough to conclude dopaminergic neuroprotective efficacy of curcumin: Insights from ALSS Drosophila Parkinson’s disease model

    bioRxiv (Cold Spring Harbor Laboratory)Preprint

All 23

More on Oxidative stress and ROS signaling

Lifespan

upin flies6upin worms4upin yeast cells3upin A. mellifera1+10

20 studies
  1. Curcumin extends lifespan in Drosophila acquiring AD-like symptoms (living 30% longer).

    “The Drosophila given curcumin showcased a significant increase in health, living 30% longer.”

    Model organismsin Drosophila acquiring AD-like symptomspowder

    A Novel AI Approach to Investigate Curcumin’s Potential to Delay Alzheimer’s Onset Using Genetically Modified Drosophila

    IEEE International Conference on Computing and Machine Intelligence (ICMI)

  2. Curcumin extends lifespan in flies.

    “extended Drosophila melanogaster lifespan (P < 0.001)”

    Model organisms

    Curcumin and nanocurcumin effects on weight, negative geotaxis, total protein, protein profiling by SDS-PAGE, and lifespan in Drosophila melanogaster

    Journal of university of Anbar for pure science

  3. Curcumin shortens lifespan in F1 offspring of curcumin-treated parental flies.

    “Unexpectedly, the F1 offspring of curcumin-treated parental flies showed a significant reduction in lifespan that was also sex-specific”

    Model organismsin F1 offspring of curcumin-treated parental flies

    Curcumin Induces Transgenerational and Sex-Specific Effects on Lifespan, Gene Expression, and Metabolism in the Fruit Fly Drosophila melanogaster

    BioFactors (Oxford, England)

  4. Curcumin extends lifespan in flies.

    “Both concentrations were found to significantly increase lifespan and climbing activity in male and female flies”

    Model organismsdietary0.1% and 1% (w/v)

    Curcumin Induces Transgenerational and Sex-Specific Effects on Lifespan, Gene Expression, and Metabolism in the Fruit Fly Drosophila melanogaster

    BioFactors (Oxford, England)

  5. Curcumin extends lifespan in yeast cells (wildtype).

    “curcumin significantly prolongs the PoMiCL of wildtype yeast cells, with the most pronounced effects observed at lower concentrations”

    Cellswildtype

    Curcumin Inhibits TORC1 and Prolongs the Lifespan of Cells with Mitochondrial Dysfunction

    Cells

  6. Curcumin extends lifespan in yeast cells (wildtype postmitotic cells).

    “curcumin significantly extends the lifespan of postmitotic wildtype yeast cells”

    Cellswildtype postmitotic cells

    Curcumin extends the lifespan of aging postmitotic cells with mitochondrial dysfunction

    bioRxiv (Cold Spring Harbor Laboratory)Preprint

  7. Curcumin extends lifespan in flies (exposed to cigarette smoke).

    “curcumin at 5 μM extended the lifespan of D. melanogaster exposed to cigarette smoke”

    Model organismsexposed to cigarette smoke5 μM

    Phenotypical and molecular assessments on the pharmacological effects of curcumin in Drosophila melanogaster

    Narra J

  8. Curcumin extends lifespan in worms.

    “curcumin extended the lifespan of nematodes”

    Model organisms

    Curcumin supplementation increases longevity and antioxidant capacity in Caenorhabditis elegans

    Frontiers in pharmacology

  9. Curcumin extends lifespan in worms.

    “in Caenorhabditis elegans, AhR mediates curcumin-induced lifespan extension”

    Model organisms

    Aryl Hydrocarbon Receptor-Dependent and -Independent Pathways Mediate Curcumin Anti-Aging Effects

    Antioxidants (Basel, Switzerland)

  10. Curcumin extends lifespan in A. mellifera (ethanol-induced lifespan shortening).

    “lifespan shortening caused by ethanol intake, was restored when curcumin and ethanol were co-administered.”

    Model organismsethanol-induced lifespan shortening

    Screening bioactive food compounds in honey bees suggests curcumin blocks alcohol-induced damage to longevity and DNA methylation

    Scientific reports

All 24

Cellular senescence

downin human cells7downin mice3downin mouse cells3upin cells2+5

20 studies
  1. Curcumin decreases cellular senescence in mouse cells (palmitic acid-induced lipotoxicity).

    “Curcumin mitigates PA-induced senescence in MIN6 cells”

    Cellspalmitic acid-induced lipotoxicityMIN6 β cell

    Curcumin mitigates palmitic acid-induced senescence in MIN6 β cells through NOX4/ROS regulation

    Archives of biochemistry and biophysics

  2. Curcumin decreases cellular senescence in mouse cells.

    “Curcumin inhibited ROS production and mitigated ADSC senescence.”

    Cells

    Curcumin controls the senescence of adipose-derived mesenchymal stem cells via the FoxO3/autophagy signaling pathway to enhance joint homeostasis for osteoarthritis therapy

    Stem cell research & therapy

  3. Curcumin decreases cellular senescence in human cells (high glucose-induced aging in HASMCs).

    “curcumin increased HASMCs viability and inhibited HG-induced vascular aging by promoting mitophagy in vitro”

    Cellshigh glucose-induced aging in HASMCshuman aortic smooth muscle cells

    Curcumin improves diabetic vascular aging rats and high glucose-induced cells aging by promoting mitophagy

    3 Biotech

  4. Curcumin decreases cellular senescence in CD8+ T cells.

    “Cur inhibited TNBC cell glycolysis and T cell senescence”

    Cellsin CD8+ T cells

    NGR-modified curcumin nanovesicles reverse immunotherapy resistance in triple-negative breast cancer via TLR9 and mTOR pathway modulation

    Cell biology and toxicology

  5. Curcumin decreases cellular senescence in diabetic mice with spinal cord injury (-34.96% ± 6.59%).

    “Treatment with PM-sEVs-Cur attenuated ECs senescence by 34.96% ± 6.59%”

    Animalsin diabetic mice with spinal cord injury

    Curcumin-loaded milk-derived sEVs fused with platelet membrane attenuate endothelial senescence and promote spinal cord injury recovery in diabetic mice

    Materials today. Bio

  6. Curcumin decreases cellular senescence in human cells (cigarette smoke extract-induced COPD in vitro model).

    “5 μM PlexoZome® curcumin demonstrated anti-senescent activity by decrease in X-gal positive cells”

    Cellscigarette smoke extract-induced COPD in vitro modelliposomal encapsulation (PlexoZome)bronchial epithelial cells5 μM

    Liposomal curcumin inhibits cigarette smoke induced senescence and inflammation in human bronchial epithelial cells

    Pathology, research and practice

  7. Curcumin inhibits cellular senescence in diabetic retinopathy.

    “Curcumin can alleviate the progression of DR by promoting RPE survival, TJ integrity, retinoid isomerase activity, RPE senescence inhibition, and neovascularization.”

    Cellsin diabetic retinopathy

    Protective Effect of Curcumin on the Tight Junction Integrity and Cellular Senescence in Human Retinal Pigment Epithelium of Early Diabetic Retinopathy

    Journal of physiological investigation

  8. Curcumin prevents cellular senescence (metabolic endotoxemia).

    “caffeine and curcumin, have shown potential in preventing endothelial cell senescence.”

    Reviewmetabolic endotoxemia

    Dose-Dependent Effects of Lipopolysaccharide on the Endothelium-Sepsis versus Metabolic Endotoxemia-Induced Cellular Senescence

    Antioxidants (Basel, Switzerland)

  9. Curcumin inhibits cellular senescence in human cells (higher passages).

    “curcumin (50 μM) significantly restored proliferation ability in DFCs and inhibited their replicative senescence.”

    Cellshigher passages50 μM

    Curcumin attenuates replicative senescence in human dental follicle cells and restores their osteogenic differentiation

    Journal of oral biosciences

  10. Curcumin decreases cellular senescence in mice (aged mice).

    “CUR supplementation led to the downregulation of senescence-associated hepatic gene expressions in both usually fed and nutritionally challenged aged mice.”

    Animalsaged miceliver

    Dietary Curcumin Attenuates Hepatic Cellular Senescence by Suppressing the MAPK/NF-κB Signaling Pathway in Aged Mice

    Antioxidants (Basel, Switzerland)

All 20

More on Cellular senescence

Body weight

downin humans11no changein humans4downin mice2upin flies1

18 studies
  1. Curcumin decreases body weight in humans (versus placebo at end of study) (p < .05 versus placebo).

    “weight, body mass index, and waist circumference of patients compared with the placebo at the end of the study (p < .05 for all)”

    Human trialversus placebo at end of study500 mg once a day8 weeksfemalesn = 48

    Effects of curcumin supplementation on metabolic parameters, inflammatory factors and obesity values in women with rheumatoid arthritis: A randomized, double-blind, placebo-controlled clinical trial

    Phytotherapy research : PTR

  2. Curcumin decreases body weight in humans (patients with metabolic syndrome).

    “Body weight decreased significantly in the curcumin group compared to placebo.”

    Human trialpatients with metabolic syndromesupplement500 mg daily12 weeksn = 66

    The Effect of Curcumin Supplementation on Pulse Wave Velocity in Patients with Metabolic Syndrome: A Randomized, Double-Blind, Placebo-Controlled Trial

    Advances in experimental medicine and biology

  3. Curcumin decreases body weight in humans (polycystic ovary syndrome) (-0.8 ± 0.9 vs. -0.2 ± 0.8 kg, P = 0.03).

    “Curcumin significantly decreased weight (-0.8 ± 0.9 vs. -0.2 ± 0.8 kg, P = 0.03)”

    Human trialpolycystic ovary syndrome500 mg/day12 weeksfemalesn = 60

    Effects of curcumin on body weight, glycemic control and serum lipids in women with polycystic ovary syndrome: A randomized, double-blind, placebo-controlled trial

    Clinical nutrition ESPEN

  4. Curcumin showed no clear effect on body weight in humans (MetS).

    “There was no significant difference between treatment and control groups in terms of weight, body mass index, waist circumference and serum cathepsin D levels before and after the intervention.”

    Human trialMetSphosphatidylcholine complex2 capsules containing 500 mg6 weeksn = 80

    Effect of Curcumin on Serum Cathepsin D in Patients with Metabolic Syndrome

    Cardiovascular & hematological disorders drug targets

  5. Curcumin decreases body weight in humans (non-alcoholic fatty liver disease) (P < 0.001).

    “weight (P < 0.001), waist circumference (P < 0.001), body fat percent (P < 0.01), and body mass index (BMI) (P < 0.01) in comparison with placebo”

    Human trialnon-alcoholic fatty liver diseasephytosomal curcumin250 mg/dayeight weeks

    Efficacy of phytosomal curcumin among patients with non-alcoholic fatty liver disease

    International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition

  6. Curcumin showed no clear effect on body weight in humans (patients with metabolic syndrome).

    “did not improve weight and glucose homeostasis in the patients with metabolic syndrome”

    Human trialpatients with metabolic syndromecapsule1890 mg/day12 weeksn = 33

    Lipid-lowering effects of curcumin in patients with metabolic syndrome: a randomized, double-blind, placebo-controlled trial

    Phytotherapy research : PTR

  7. Curcumin increases body weight in flies.

    “increased weight (P < 0.01)”

    Model organisms

    Curcumin and nanocurcumin effects on weight, negative geotaxis, total protein, protein profiling by SDS-PAGE, and lifespan in Drosophila melanogaster

    Journal of university of Anbar for pure science

  8. Curcumin decreases body weight in humans (nonalcoholic fatty liver disease) (MD = -2.15; 95% CI = -3.78 to -0.53).

    “weight (MD = -2.15; 95% CI = -3.78 to -0.53; P = .01)”

    Reviewnonalcoholic fatty liver disease

    Influence of phytosomal curcumin on anthropometric indices for nonalcoholic fatty liver disease: A meta-analysis

    Medicine

  9. Curcumin decreases body weight in mice (HFHSD-fed) (10.84 ± 1.09 g vs. 15.28 ± 1.26 g).

    “cumulative body weight gain after 8 weeks in the aged female mice supplemented with curcumin and fed an HFHSD was significantly lower (10.84 ± 1.09 g) compared to those fed a HFHSD alone (15.28 ± 1.26 g)”

    AnimalsHFHSD-fed0.4% w/w8-weekfemales

    Curcumin-Rich Diet Mitigates Non-Alcoholic Fatty Liver Disease (NAFLD) by Attenuating Fat Accumulation and Improving Insulin Sensitivity in Aged Female Mice under Nutritional Stress

    Biology

  10. Curcumin decreases body weight in humans (NAFLD) (WMD -0.81 (95% CI -1.28 to -0.35)).

    “was associated with significant reductions in levels of FBG, HOMA-IR, TG, TC, LDL, weight and BMI in patients with NAFLD.”

    ReviewNAFLD50–3000 mg/day8–12 weeksn = 1,191

    Curcumin effects on glycaemic indices, lipid profile, blood pressure, inflammatory markers and anthropometric measurements of non-alcoholic fatty liver disease patients: A systematic review and meta-analysis of randomized clinical trials

    Complementary therapies in medicine

All 18

Triglyceride

downin humans12no changein humans1upin humans1

14 studies
  1. Curcumin decreases triglyceride in humans (Brazilian women with high waist circumference) (p < 0.001 for TGs, p = 0.001 for TC).

    “TGs (p < 0.001) and TC (p = 0.001) compared with the PG”

    Human trialBrazilian women with high waist circumferencecapsule (Curcumin C3 Complex®)500 mg/day90 daysfemalesn = 35

    Curcumin supplementation reduces blood glucose and serum lipids of Brazilian women with high waist circumference: a randomized clinical trial

    Archives of endocrinology and metabolism

  2. Curcumin decreases triglyceride in humans (versus placebo at end of study) (p < .05 versus placebo).

    “Curcumin supplementation significantly decreased homeostatic model assessment for insulin resistance (HOMA-IR), erythrocyte sedimentation rate, serum levels of high-sensitivity C-reactive protein and triglycerides”

    Human trialversus placebo at end of study500 mg once a day8 weeksfemalesn = 48

    Effects of curcumin supplementation on metabolic parameters, inflammatory factors and obesity values in women with rheumatoid arthritis: A randomized, double-blind, placebo-controlled clinical trial

    Phytotherapy research : PTR

  3. Curcumin decreases triglyceride in humans (nano-micelle curcumin versus placebo) (change -60.5 ± 121.7 vs 13.1 ± 78.1 mg/dL between groups).

    “a significant reduction in the average change of triglyceride (TG) levels (-60.5 ± 121.7 vs. 13.1 ± 78.1 mg/dL; p < .05)”

    Human trialnano-micelle curcumin versus placebonano-micelle80 mg/day12 weeksn = 50

    The effects of nano-curcumin supplementation on glycemic control, blood pressure, lipid profile, and insulin resistance in patients with the metabolic syndrome: A randomized, double-blind clinical trial

    Phytotherapy research : PTR

  4. Curcumin decreases triglyceride in humans (versus placebo; phytosomal formulation with phosphatidylserine and piperine).

    “FPI, TG, liver transaminases, fatty liver index and serum cortisol level also significantly improved compared with the placebo-treated group.”

    Human trialversus placebo; phytosomal formulation with phosphatidylserine and piperineCurserin800 mg (2 tablets per day)8 weeksn = 80

    Effects of phytosomal curcumin on anthropometric parameters, insulin resistance, cortisolemia and non-alcoholic fatty liver disease indices: a double-blind, placebo-controlled clinical trial

    European journal of nutrition

  5. Curcumin decreases triglyceride in humans (nonalcoholic fatty liver disease) (P < 0.001).

    “triglycerides (P < 0.001)”

    Human trialnonalcoholic fatty liver disease1000 mg/d8 weeksn = 87

    Curcumin Lowers Serum Lipids and Uric Acid in Subjects With Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial

    Journal of cardiovascular pharmacology

  6. Curcumin decreases triglyceride in humans (patients with metabolic syndrome) (reduction of 65 mg/dL).

    “The triglyceride-lowering effect, a reduction of 65 mg/dL, was also found in this study.”

    Human trialpatients with metabolic syndromecapsule1890 mg/day12 weeksn = 33

    Lipid-lowering effects of curcumin in patients with metabolic syndrome: a randomized, double-blind, placebo-controlled trial

    Phytotherapy research : PTR

  7. Curcumin decreases triglyceride in humans (healthy).

    “lowering of plasma triglyceride values”

    Human trialhealthylipidatedplasma80 mg/day4 wkn = 19

    Diverse effects of a low dose supplement of lipidated curcumin in healthy middle aged people

    Nutrition journal

  8. Curcumin increases triglyceride in ACS patients.

    “finally the high-dose curcumin that showed the highest effect of increase.”

    Human trialin ACS patientshigh dose 3 times 60 mg/day

    The effect of curcumin on lipid level in patients with acute coronary syndrome

    Acta medica Indonesiana

  9. Curcumin decreases triglyceride in adults with prediabetes or type 2 diabetes (WMD: -13.73 mg/dL; 95% CI: -19.49, -7.96).

    “Curcumin/turmeric supplementation significantly reduced triglycerides (WMD: -13.73 mg/dL; 95% CI: -19.49, -7.96)”

    Reviewin adults with prediabetes or type 2 diabetes

    Effects of Curcumin/Turmeric Supplementation on Lipid Profile in Subjects With Prediabetes and Diabetes: A Systematic Review and Meta-Analysis

    Lipids

  10. Curcumin decreases triglyceride in humans (updated meta-analysis of RCTs) (MD -13.15 mg/dL (95% CI: -17.31, -8.98)).

    “and TG, with mean differences (MDs) of -7.76 mg/dL (95% CI: -11.29, -4.22; I2 = 97%), -5.84 mg/dL (95% CI: -11.63, -0.05; I2 = 98%), and -13.15 mg/dL (95% CI: -17.31, -8.98”

    Reviewupdated meta-analysis of RCTs

    An Umbrella Review of Systematic Reviews and Meta-analyses of Randomized Controlled Trials Investigating the Effect of Curcumin Supplementation on Lipid Profiles

    Nutrition reviews

All 14

More on Triglyceride

C-reactive protein

downin humans9downin rats3no changein humans1downin reviews1

14 studies
  1. Curcumin decreases C-reactive protein in obese patients with type 2 diabetes, versus placebo.

    “High-sensitivity C-reactive protein, interleukin-1 beta, interleukin-6, and tumor necrosis factor-alpha were also significantly lower in the curcumin group, with p values less than 0.001.”

    Human trialin obese patients with type 2 diabetes, versus placebo12 months

    The Effect of Curcumin on Reducing Atherogenic Risks in Obese Patients with Type 2 Diabetes: A Randomized Controlled Trial

    Nutrients

  2. Curcumin decreases C-reactive protein in type 2 diabetic patients with mild to moderate CAD (P < 0.001).

    “Nano-curcumin significantly mitigated the hs-CRP and LipoPr (a) levels following 90 days of treatment”

    Human trialin type 2 diabetic patients with mild to moderate CAD80 mg/day90 daysn = 64

    Three months of combination therapy with nano-curcumin reduces the inflammation and lipoprotein (a) in type 2 diabetic patients with mild to moderate coronary artery disease: Evidence of a randomized, double-blinded, placebo-controlled clinical trial

    BioFactors (Oxford, England)

  3. Curcumin decreases C-reactive protein in humans (versus placebo at end of study) (p < .05 versus placebo).

    “Curcumin supplementation significantly decreased homeostatic model assessment for insulin resistance (HOMA-IR), erythrocyte sedimentation rate, serum levels of high-sensitivity C-reactive protein and triglycerides”

    Human trialversus placebo at end of study500 mg once a day8 weeksfemalesn = 48

    Effects of curcumin supplementation on metabolic parameters, inflammatory factors and obesity values in women with rheumatoid arthritis: A randomized, double-blind, placebo-controlled clinical trial

    Phytotherapy research : PTR

  4. Curcumin decreases C-reactive protein in humans.

    “nano-curcumin supplementation significantly decreases serum concentrations of malondialdehyde (MDA), and hs-CRP in subjects with metabolic syndrome.”

    Human trialnano-curcumin6 weeksfemales

    Aerobic exercise and nano-curcumin supplementation improve inflammation in elderly females with metabolic syndrome

    Diabetology & metabolic syndrome

  5. Curcumin decreases C-reactive protein.

    “Curcumin increases microbiota diversity and lowers C-Reactive Protein (CRP) and Tumor Necrosis Factor α (TNF-α) levels.”

    Review

    Age Versus Immunity: Dietary Influences on Immunosenescence

    Journal of clinical medicine

  6. Curcumin decreases C-reactive protein in type 2 diabetes (SMD = -0.59, 95%CI (-1.11, -0.07), p = 0.03).

    “there was a significant decrease in C-Reactive Protein in curcumin compared to a placebo, SMD = -0.59, 95%CI (-1.11, -0.07), p = 0.03”

    Reviewin type 2 diabetesn = 1,382

    Curcumin Attenuates Hyperglycemia and Inflammation in Type 2 Diabetes Mellitus: Quantitative Analysis of Randomized Controlled Trial

    Nutrients

  7. Curcumin decreases C-reactive protein in humans (WMD = -0.87, 95% CI: -1.14 to -0.59).

    “curcumin significantly reduced CRP (weighted mean difference (WMD) = -0.87; 95 % CI: - 1.14, - 0.59, P< 0.001)”

    Review

    The effects of curcumin supplementation on biomarkers of inflammation, oxidative stress, and endothelial function: A meta-analysis of meta-analyses

    Prostaglandins & other lipid mediators

  8. Curcumin decreases C-reactive protein in humans (polycystic ovary syndrome) (WMD -0.785, 95% CI -1.553 to -0.017).

    “C-reactive protein (WMD -0.785, 95% CI -1.553 to -0.017, P = 0.045, I2 = 23.9%)”

    Reviewpolycystic ovary syndrome

    Therapeutic effect and safety of curcumin in women with PCOS: A systematic review and meta-analysis

    Frontiers in endocrinology

  9. Curcumin decreases C-reactive protein in humans (hemodialysis) (WMD -3.3 mg/L, 95% CI -5.4 to -1.3).

    “curcumin-containing supplement had significant effect on serum C-reactive protein (CRP) levels (WMD = -3.3 mg/L; 95% CI: -5.4 to -1.3; p < 0.001”

    Reviewhemodialysisn = 467

    The effects of curcumin-containing supplements on inflammatory biomarkers in hemodialysis patients: A systematic review and meta-analysis

    Phytotherapy research : PTR

  10. Curcumin decreases C-reactive protein in rats.

    “Serum CRP means significantly decreased in all experimental groups compared to C and S groups.”

    Animalsplasma-serum8 weeks

    Effects of Interval Training Intensity and Curcumin on expression of Endothelial Progenitor Cells mRNA and C Reactive Protein in Elderly Rats Heart

    La Clinica terapeutica

All 14

More on C-reactive protein

Fasting blood glucose

downin humans12

12 studies
  1. Curcumin decreases fasting blood glucose in humans.

    “The means of diabetes-related blood chemistries used to assess diabetic progression, such as HbA1c, FPG, were significantly lower in the curcumin-treated group compared to the placebo group at visits at 3,6, 9, and 12 months.”

    Human trial12 monthsn = 229

    Curcumin extract improves beta cell functions in obese patients with type 2 diabetes: a randomized controlled trial

    Nutrition journal

  2. Curcumin decreases fasting blood glucose in humans (type 2 diabetes) (115.49 vs. 130.71, P < 0.05).

    “curcumin-treated group showed a significant decrease in fasting blood glucose (115.49 vs.130.71; P < 0.05), HbA1c (6.12 vs. 6.47; P < 0.05)”

    Human trialtype 2 diabetes1500 mg/day12 monthsn = 272

    Curcumin extract improves beta cell functions in obese patients with type 2 diabetes: a randomized controlled trial

    Nutrition journal

  3. Curcumin decreases fasting blood glucose in humans (P = 0.007).

    “Curcumin decreased significantly fasting blood glucose (P = 0.007)”

    Human trialcapsules500 milligram twice/dailyeight weeksfemales

    Curcumin and vitamin E improve hot flashes, lipid profile, and fasting blood glucose without any detrimental effect on the liver and renal function in postmenopausal women: A triple-blind placebo-controlled clinical trial

    Health care for women international

  4. Curcumin decreases fasting blood glucose in patients with diabetic foot ulcer (p = .02).

    “Curcumin intake significantly decreased fasting plasma glucose (p = .02), insulin (p = .01), insulin resistance (p = .02), and significantly increased insulin sensitivity (p = .008) compared with the placebo.”

    Human trialin patients with diabetic foot ulcernanocurcumin80 mg daily12 weeksn = 60

    The effects of curcumin intake on wound healing and metabolic status in patients with diabetic foot ulcer: A randomized, double-blind, placebo-controlled trial

    Phytotherapy research : PTR

  5. Curcumin decreases fasting blood glucose in humans (p = 0.02).

    “fasting blood sugar (p = 0.02), and HOMA-IR (p = 0.01) compared with controls”

    Review

    Effect of curcumin on cardiometabolic diseases in the elderly: A systematic review of randomized controlled trials

    Ageing research reviews

  6. Curcumin decreases fasting blood glucose in type 2 diabetes (MD = -11.48 mg/dL, 95%CI (-14.26, -8.70), p < 0.01).

    “Supplementation with curcumin led to a significant decrease in fasting blood glucose, MD = -11.48 mg/dL, 95%CI (-14.26, -8.70), p < 0.01”

    Reviewin type 2 diabetesn = 1,382

    Curcumin Attenuates Hyperglycemia and Inflammation in Type 2 Diabetes Mellitus: Quantitative Analysis of Randomized Controlled Trial

    Nutrients

  7. Curcumin decreases fasting blood glucose in humans.

    “curcumin supplementation can modify FBS and some glycemic indices, lipid parameters, as well as inflammatory and oxidative parameters.”

    Reviewn = 7,216

    Curcumin on Human Health: A Comprehensive Systematic Review and Meta-Analysis of 103 Randomized Controlled Trials

    Phytotherapy research : PTR

  8. Curcumin decreases fasting blood glucose in humans (NAFLD) (WMD -2.83 (95% CI -4.61 to -1.06)).

    “was associated with significant reductions in levels of FBG, HOMA-IR, TG, TC, LDL, weight and BMI in patients with NAFLD.”

    ReviewNAFLD50–3000 mg/day8–12 weeksn = 1,191

    Curcumin effects on glycaemic indices, lipid profile, blood pressure, inflammatory markers and anthropometric measurements of non-alcoholic fatty liver disease patients: A systematic review and meta-analysis of randomized clinical trials

    Complementary therapies in medicine

  9. Curcumin decreases fasting blood glucose in humans (disturbed glycemia) (WMD: -4.60 mg/dl, 95% CI: -5.55 to -3.66).

    “turmeric/curcumin supplementation was significantly effective in improving fasting blood sugar (WMD: 4.60 mg/dl; 95% CI: 5.55, -3.66)”

    Reviewdisturbed glycemia

    Effects of curcumin/turmeric supplementation on glycemic indices in adults: A grade-assessed systematic review and dose-response meta-analysis of randomized controlled trials

    Diabetes & metabolic syndrome

  10. Curcumin decreases fasting blood glucose in humans (polycystic ovary syndrome) (MD = -3.67, 95% CI [-5.25, -2.08], p < .00001).

    “CUR was associated with a statistically significant improvement in the glycemic control including fasting blood glucose (MD = -3.67; 95% CI = [-5.25, -2.08], p < .00001)”

    Reviewpolycystic ovary syndromen = 296

    The effects of curcumin as dietary supplement for patients with polycystic ovary syndrome: An updated systematic review and meta-analysis of randomized clinical trials

    Phytotherapy research : PTR

All 13

More on Fasting blood glucose

Total cholesterol

downin humans9no changein humans1

10 studies
  1. Curcumin decreases total cholesterol in humans (P = 0.015).

    “total cholesterol (P = 0.015), and triglyceride (P = 0.007) compared to placebo”

    Human trialcapsules500 milligram twice/dailyeight weeksfemales

    Curcumin and vitamin E improve hot flashes, lipid profile, and fasting blood glucose without any detrimental effect on the liver and renal function in postmenopausal women: A triple-blind placebo-controlled clinical trial

    Health care for women international

  2. Curcumin decreases total cholesterol in patients with diabetes on hemodialysis (β = -17.83 mg/dL, 95% CI: -29.22 to -6.45).

    “Nanocurcumin treatment was associated with a significant reduction in triglycerides (β = -16.13 mg/dL, 95% CI: -31.51 to -0.75; P < .05), VLDL-cholesterol (β = -3.22 mg/dL, 95% CI: -6.30 to -0.15; P < .05), total cholesterol (β = -17.83 mg/dL, 95% CI: -29.22 to -6.45; P < .05)”

    Human trialin patients with diabetes on hemodialysis80 mg/d12 weeksn = 60

    The Effects of Nano-curcumin on Metabolic Status in Patients With Diabetes on Hemodialysis, a Randomized, Double Blind, Placebo-controlled Trial

    Iranian journal of kidney diseases

  3. Curcumin decreases total cholesterol in humans (polycystic ovary syndrome) (β -15.86 mg/dL (95% CI, -24.48, -7.24)).

    “taking curcumin was associated with a significant reduction in total cholesterol (β -15.86 mg/dL; 95% CI, -24.48, -7.24; P = 0.001)”

    Human trialpolycystic ovary syndrome500 mg/day12 weeksfemalesn = 60

    Effects of curcumin on body weight, glycemic control and serum lipids in women with polycystic ovary syndrome: A randomized, double-blind, placebo-controlled trial

    Clinical nutrition ESPEN

  4. Curcumin decreases total cholesterol in humans (nonalcoholic fatty liver disease) (P < 0.001).

    “Supplementation with curcumin was associated with a reduction in serum levels of total cholesterol (P < 0.001)”

    Human trialnonalcoholic fatty liver disease1000 mg/d8 weeksn = 87

    Curcumin Lowers Serum Lipids and Uric Acid in Subjects With Nonalcoholic Fatty Liver Disease: A Randomized Controlled Trial

    Journal of cardiovascular pharmacology

  5. Curcumin decreases total cholesterol in humans (NAFLD) (WMD -11.81 (95% CI -19.65 to -3.96)).

    “was associated with significant reductions in levels of FBG, HOMA-IR, TG, TC, LDL, weight and BMI in patients with NAFLD.”

    ReviewNAFLD50–3000 mg/day8–12 weeksn = 1,191

    Curcumin effects on glycaemic indices, lipid profile, blood pressure, inflammatory markers and anthropometric measurements of non-alcoholic fatty liver disease patients: A systematic review and meta-analysis of randomized clinical trials

    Complementary therapies in medicine

  6. Curcumin decreases total cholesterol in humans (polycystic ovary syndrome) (WMD -15.591, 95% CI -27.908 to -3.273).

    “total cholesterol (WMD -15.591, 95% CI -27.908 to -3.273, P = 0.013, I2 = 68.9%)”

    Reviewpolycystic ovary syndrome

    Therapeutic effect and safety of curcumin in women with PCOS: A systematic review and meta-analysis

    Frontiers in endocrinology

  7. Curcumin decreases total cholesterol in humans (ES = -0.81 mg/dl, 95% CI: -1.39 to -0.24).

    “curcumin supplementation was effective on reduction of total cholesterol (TC) (ES = -0.81 mg/dl; 95% CI: 1.39, -0.24, p = 0.006”

    Review

    Curcumin as a novel approach in improving lipid profile: An umbrella meta-analysis

    Nutrition, metabolism, and cardiovascular diseases : NMCD

  8. Curcumin decreases total cholesterol in humans (polycystic ovary syndrome) (MD = -15.55, 95% CI [-30.33, -0.76], p < .04).

    “The mean difference in total cholesterol was also statistically significant (MD = -15.55; 95% CI = [-30.33, -0.76], p < .04).”

    Reviewpolycystic ovary syndromen = 296

    The effects of curcumin as dietary supplement for patients with polycystic ovary syndrome: An updated systematic review and meta-analysis of randomized clinical trials

    Phytotherapy research : PTR

  9. Curcumin decreases total cholesterol in humans (polycystic ovary syndrome) (MD -12.45, 95% CI -22.05 to -2.85).

    “It also significantly improves high-density lipoprotein (MD: 1.92, 95% CI: 0.33-3.51) and total cholesterol (MD: -12.45, 95% CI: -22.05 to -2.85).”

    Reviewpolycystic ovary syndrome

    Effects of Curcumin on Glycemic Control and Lipid Profile in Polycystic Ovary Syndrome: Systematic Review with Meta-Analysis and Trial Sequential Analysis

    Nutrients

  10. Curcumin showed no clear effect on total cholesterol in humans (8.97 (95% CI: -4.56 to 22.51) mg/dL, p = 0.19).

    “Meta-analysis of findings did not indicate a significant effect of curcumin on any of the lipid parameters.”

    Review

    A systematic review and meta-analysis of randomized controlled trials investigating the effects of curcumin on blood lipid levels

    Clinical nutrition (Edinburgh, Scotland)

More on Total cholesterol

HbA1c

downin humans8no changein humans1

9 studies
  1. Curcumin decreases HbA1c in humans.

    “curcumin supplementation (MD = −.49, CI [−.70; −.28]), dual GLP-1 + GIP RAs (MD = −.46, CI [−.63; −.29]), single GLP-1 RAs (MD = −.41, CI [−.50; −.31]), physical activity (MD = −.35, CI [−.47; −.24]) and metformin + DPP-4 (MD = −.30, CI [−.55; −.05]) were the most effective and the only ones to obtain a clinically significant reduction of HbA1c (≥.3%23”

    Human trialn = 37,548

    Evidence-based ranking of diabetes prevention in prediabetes: A comprehensive network meta-analysis of 378 randomised controlled trials

    Clinical and translational medicine

  2. Curcumin decreases HbA1c in humans (diabetic macular edema; adjunct to intravitreal bevacizumab versus matched placebo) (Greater reduction: MD 0.63%, 95% CI 0.3–1.0; P < 0.001).

    “Adjunctive treatment with oral curcumin in patients receiving IVB for DME was associated with a significantly greater reduction in HbA1c levels.”

    Human trialdiabetic macular edema; adjunct to intravitreal bevacizumab versus matched placebooral capsules40 mg every 12 h3 monthsn = 52

    Short-term effects of oral curcumin as adjunct to intravitreal bevacizumab in diabetic macular edema: a randomized clinical trial

    International journal of retina and vitreous

  3. Curcumin decreases HbA1c in humans.

    “Although no significant group × time interaction was observed (p = 0.217), the curcumin-supplemented group showed a significant reduction in HbA1c levels (p = 0.044, 95% CI: 0.006 to 0.494), while levels remained stable in the placebo group (p > 0.999, 95% CI: −0.260 to 0.348).”

    Human trial12 weeksn = 23

    Twelve-Week Curcumin Supplementation Improves Glucose Homeostasis and Gut Health in Prediabetic Older Adults: A Pilot, Double-Blind, Placebo-Controlled Trial

    Nutrients

  4. Curcumin showed no clear effect on HbA1c in humans.

    “The primary endpoint, HbA1c, did not differ significantly between the two groups.”

    Human trialpatients with impaired glucose tolerance or non-insulin-dependent diabetes mellitus, versus placebohighly absorbable preparation (Theracurmin)180 mg daily6 months

    Effects of Highly Absorbable Curcumin in Patients with Impaired Glucose Tolerance and Non-Insulin-Dependent Diabetes Mellitus

    Journal of diabetes research

  5. Curcumin decreases HbA1c in humans (ES: -0.44; 95 % CI: -0.67, -0.21).

    “curcumin supplements leads to a significant decrease in fasting blood sugar levels (FBS) (ES: -1.63; 95 % CI: -2.36, -0.89, P<0.001; I2=88.4 %, P<0.001), homeostasis model assessment-estimated insulin resistance (HOMA-IR) (ES: -0.38; 95 % CI: -0.48, -0.28, P<0.001; I2=35.9 %, P=0.142), hemoglobin A1c (HbA1c) (ES: -0.44; 95 % CI: -0.67, -0.21, P<0.001; I2=65.0 %, P=0.014), and insulin”

    Review

    The effect of curcumin supplementation on glycemic indices in adults: A meta-analysis of meta-analyses

    Prostaglandins & other lipid mediators

  6. Curcumin decreases HbA1c in humans (disturbed glycemia) (WMD: -0.32%, 95% CI: -0.45 to -0.19).

    “hemoglobin A1c (HbA1c) (WMD: 0.32%; 95% CI: 0.45, -0.19)”

    Reviewdisturbed glycemia

    Effects of curcumin/turmeric supplementation on glycemic indices in adults: A grade-assessed systematic review and dose-response meta-analysis of randomized controlled trials

    Diabetes & metabolic syndrome

  7. Curcumin decreases HbA1c in humans (uncomplicated type 2 diabetes) (p = 0.008).

    “glycosylated hemoglobin, homeostasis model assessment (HOMA), and low-density lipoprotein (LDL) showed a statistically significant reduction in subjects that were treated with curcumin”

    Reviewuncomplicated type 2 diabetes

    Potential Therapeutic Effects of Curcumin on Glycemic and Lipid Profile in Uncomplicated Type 2 Diabetes-A Meta-Analysis of Randomized Controlled Trial

    Nutrients

  8. Curcumin decreases HbA1c in humans (type 2 diabetes mellitus).

    “Treatment with curcumin significantly reduced the level of FBS and HbA1c in 8 and 7 studies, respectively.”

    Reviewtype 2 diabetes mellitus

    Effect of Curcumin on Glycemic Control in Patients with Type 2 Diabetes: A Systematic Review of Randomized Clinical Trials

    Advances in experimental medicine and biology

  9. Curcumin decreases HbA1c in humans (-0.54, 95% CI: [-1.09 to -0.002] %).

    “Supplementation of curcuminoids and/or curcumin decreased the concentrations of HbA1c (-0.54, 95% CI: [-1.09 to -0.002] %, p = 0.049)”

    Review≥4 weeks

    Curcumin or combined curcuminoids are effective in lowering the fasting blood glucose concentrations of individuals with dysglycemia: Systematic review and meta-analysis of randomized controlled trials

    Pharmacological research

More on HbA1c

HOMA-IR

downin humans6no changein humans1downin rats1

8 studies
  1. Curcumin decreases HOMA-IR in humans (versus placebo at end of study) (p < .05 versus placebo).

    “Curcumin supplementation significantly decreased homeostatic model assessment for insulin resistance (HOMA-IR)”

    Human trialversus placebo at end of study500 mg once a day8 weeksfemalesn = 48

    Effects of curcumin supplementation on metabolic parameters, inflammatory factors and obesity values in women with rheumatoid arthritis: A randomized, double-blind, placebo-controlled clinical trial

    Phytotherapy research : PTR

  2. Curcumin decreases HOMA-IR in humans (added to metformin compared with metformin alone).

    “After treatment, fasting insulin, HOMA-IR, and total testosterone in group 2 were significantly lower than those in group 1 (p < 0.05).”

    Human trialadded to metformin compared with metformin alonenanomicelle80 mg/day3 monthsfemalesn = 100

    Therapeutic Effect of Curcumin in Women with Polycystic Ovary Syndrome Receiving Metformin: A Randomized Controlled Trial

    Advances in experimental medicine and biology

  3. Curcumin decreases HOMA-IR in humans.

    “The means of HOMA-IR of the curcumin-treated group were lower than those of placebo group at all follow-up visits (3, 6, and 9 months).”

    Human trial9 monthsn = 237

    Curcumin extract for prevention of type 2 diabetes

    Diabetes care

  4. Curcumin decreases HOMA-IR in humans (3.22 vs. 4.04 (P < 0.001)).

    “The curcumin-treated group showed a lower level of HOMA-IR (3.22 vs. 4.04; P < 0.001)”

    Human trial9 monthsn = 240

    Curcumin extract for prevention of type 2 diabetes

    Diabetes care

  5. Curcumin decreases HOMA-IR in humans (overweight or obesity without type 2 diabetes).

    “Only curcumin significantly reduced HOMA-IR (MD = −0.30 [−0.53, −0.07], p = 0.019; moderate certainty), with low heterogeneity.”

    Reviewoverweight or obesity without type 2 diabetes≥4 weeks

    Effects of Bioactive Compound Supplementation on Insulin Resistance and Systemic Inflammation in Overweight and Obese Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

    Nutrients

  6. Curcumin decreases HOMA-IR in humans (uncomplicated type 2 diabetes) (p < 0.001).

    “glycosylated hemoglobin, homeostasis model assessment (HOMA), and low-density lipoprotein (LDL) showed a statistically significant reduction in subjects that were treated with curcumin”

    Reviewuncomplicated type 2 diabetes

    Potential Therapeutic Effects of Curcumin on Glycemic and Lipid Profile in Uncomplicated Type 2 Diabetes-A Meta-Analysis of Randomized Controlled Trial

    Nutrients

  7. Curcumin decreases HOMA-IR in humans (type 2 diabetes mellitus).

    “HOMA-IR was evaluated in five studies, and this was reduced significantly by curcumin supplementation in three of those studies.”

    Reviewtype 2 diabetes mellitus

    Effect of Curcumin on Glycemic Control in Patients with Type 2 Diabetes: A Systematic Review of Randomized Clinical Trials

    Advances in experimental medicine and biology

  8. Curcumin showed no clear effect on HOMA-IR in humans (-1.26, 95% CI: [-3.71 to -1.19]).

    “but were not able to decrease HOMA-IR (-1.26, 95% CI: [-3.71 to -1.19], p = 0.31).”

    Review≥4 weeks

    Curcumin or combined curcuminoids are effective in lowering the fasting blood glucose concentrations of individuals with dysglycemia: Systematic review and meta-analysis of randomized controlled trials

    Pharmacological research

  9. Curcumin decreases HOMA-IR in rats (vs. the placebo group following detraining and ad libitum feeding).

    “Curcumin reduced insulin AUC, HOMA-IR, and CRP vs. the placebo group (all P < 0.05).”

    Animalsvs. the placebo group following detraining and ad libitum feeding200 mg/kg1 wk

    Curcumin limits weight gain, adipose tissue growth, and glucose intolerance following the cessation of exercise and caloric restriction in rats

    Journal of applied physiology (Bethesda, Md. : 1985)

More on HOMA-IR

Cognitive function

upin humans3no changein humans2upin reviews2upin rats1

8 studies
  1. Curcumin showed no clear effect on cognitive function in humans.

    “When compared with the placebo group, curcumin did not improve processing speed, executive function, memory, or language at 12 months.”

    Human trial12 monthsn = 88

    Curcumin Supplementation and Vascular and Cognitive Function in Chronic Kidney Disease: A Randomized Controlled Trial

    Antioxidants (Basel, Switzerland)

  2. Curcumin improves cognitive function in humans.

    “One hour after administration curcumin significantly improved performance on sustained attention and working memory tasks, compared with placebo.”

    Human trialsolid lipid curcumin formulation (400 mg as Longvida®)400 mg1 hn = 60

    Investigation of the effects of solid lipid curcumin on cognition and mood in a healthy older population

    Journal of psychopharmacology (Oxford, England)

  3. Curcumin improves cognitive function in humans.

    “Curcumin supplementation (Longvida®, Theracurmin®, and CurQfen®) has shown significant benefits for cognitive function in humans.”

    Review

    Curcumin and Cognitive Health: Insights from Randomized Controlled Trials

    Current pharmaceutical design

  4. Curcumin improves cognitive function in a comorbid AD and GU rat model.

    “Cur-CSNP treatment significantly improved cognitive performance”

    Animalsin a comorbid AD and GU rat modelmales

    Dual protective role of curcumin- encapsulated chitosan nanoparticles against gastric and neural injury in a rat model of gut-brain axis dysfunction: a histological and biochemical study

    Naunyn-Schmiedeberg's archives of pharmacology

  5. Curcumin improves cognitive function (aging and neurodegenerative disorders).

    “has gained significant attention for its neuroprotective properties, particularly in enhancing cognitive function through epigenetic mechanisms.”

    Reviewaging and neurodegenerative disorders

    Curcumin and neuroplasticity: epigenetic mechanisms underlying cognitive enhancement in aging and neurodegenerative disorders

    Frontiers in aging neuroscience

  6. Curcumin showed no clear effect on cognitive function in humans (SMD = 0.14, 95 % CI: -0.78 to 1.07).

    “Overall, curcumin showed no significant effect on global cognitive outcomes compared to placebo (SMD = 0.14, 95 % CI: -0.78 to 1.07).”

    Reviewn = 531

    Targeting cognitive aging with curcumin supplementation: A systematic review and meta-analysis

    The journal of prevention of Alzheimer's disease

  7. Curcumin improves cognitive function in animal models of Alzheimer's disease and aging.

    “Overall, animal research has shown very promising results in potentiating cognition, both physiologically and behaviourally.”

    Reviewin animal models of Alzheimer's disease and aging

    The effect of curcumin on cognition in Alzheimer's disease and healthy aging: A systematic review of pre-clinical and clinical studies

    Brain research

  8. Curcumin improves cognitive function in older adults (SMD = 0.33, 95% CI [0.05, 0.62], p = 0.02).

    “For older adults who received curcumin, scores on measures of cognitive function (SMD = 0.33, 95% confidence interval [CI] [0.05, 0.62]; p = 0.02)”

    Reviewin older adults

    Curcumin intervention for cognitive function in different types of people: A systematic review and meta-analysis

    Phytotherapy research : PTR

LDL cholesterol

downin humans6no changein humans2

8 studies
  1. Curcumin decreases LDL cholesterol in patients with diabetic foot ulcer (p < .001).

    “curcumin intake led to a significant reduction in total- (p < .001), LDL-cholesterol (p < .001)”

    Human trialin patients with diabetic foot ulcernanocurcumin80 mg daily12 weeksn = 60

    The effects of curcumin intake on wound healing and metabolic status in patients with diabetic foot ulcer: A randomized, double-blind, placebo-controlled trial

    Phytotherapy research : PTR

  2. Curcumin decreases LDL cholesterol in humans.

    “Curcumin was associated with significantly reduced total and LDL cholesterol and had no effect on hematological safety measures.”

    Human trialsolid lipid curcumin formulation (400 mg as Longvida®)400 mg4 weeksn = 60

    Investigation of the effects of solid lipid curcumin on cognition and mood in a healthy older population

    Journal of psychopharmacology (Oxford, England)

  3. Curcumin decreases LDL cholesterol in ACS patients.

    “the administration of low-dose curcumin showed a trend of reduction in total cholesterol level and LDL cholesterol level in ACS patients.”

    Human trialin ACS patientslow dose 3 times 15 mg/day

    The effect of curcumin on lipid level in patients with acute coronary syndrome

    Acta medica Indonesiana

  4. Curcumin decreases LDL cholesterol in humans (updated meta-analysis of RCTs) (MD -5.84 mg/dL (95% CI: -11.63, -0.05)).

    “Curcumin significantly reduced TC, LDL-c, and TG, with mean differences (MDs) of -7.76 mg/dL (95% CI: -11.29, -4.22; I2 = 97%), -5.84 mg/dL (95% CI: -11.63, -0.05; I2 = 98%)”

    Reviewupdated meta-analysis of RCTs

    An Umbrella Review of Systematic Reviews and Meta-analyses of Randomized Controlled Trials Investigating the Effect of Curcumin Supplementation on Lipid Profiles

    Nutrition reviews

  5. Curcumin decreases LDL cholesterol in humans (turmeric/curcumin supplementation) (WMD -4.89 mg/dL (95% CI -5.92 to -3.87)).

    “LDL-c (WMD = -4.89 mg/dL; 95% CI = -5.92, -3.87)”

    Reviewturmeric/curcumin supplementation

    Effects of curcumin/turmeric supplementation on lipid profile: A GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials

    Complementary therapies in medicine

  6. Curcumin showed no clear effect on LDL cholesterol in humans (polycystic ovary syndrome) (MD -6.02, 95% CI -26.66 to 14.62).

    “there is no statistically significant difference in the improvement in low-density lipoprotein (MD: -6.02, 95% CI: -26.66 to 14.62) and triglyceride (MD: 8.22, 95% CI: -26.10 to 42.53) between curcumin and placebo.”

    Reviewpolycystic ovary syndrome

    Effects of Curcumin on Glycemic Control and Lipid Profile in Polycystic Ovary Syndrome: Systematic Review with Meta-Analysis and Trial Sequential Analysis

    Nutrients

  7. Curcumin decreases LDL cholesterol in humans (uncomplicated type 2 diabetes) (p = 0.021).

    “glycosylated hemoglobin, homeostasis model assessment (HOMA), and low-density lipoprotein (LDL) showed a statistically significant reduction in subjects that were treated with curcumin”

    Reviewuncomplicated type 2 diabetes

    Potential Therapeutic Effects of Curcumin on Glycemic and Lipid Profile in Uncomplicated Type 2 Diabetes-A Meta-Analysis of Randomized Controlled Trial

    Nutrients

  8. Curcumin showed no clear effect on LDL cholesterol in humans (patients with metabolic syndrome and related disorders) (SMD -0.52; 95% CI, -1.14, 0.11; P=0.10).

    “We found no significant effect of curcumin supplementation on LDL- (SMD -0.52; 95% CI, -1.14, 0.11; P=0.10) and HDL-cholesterol levels”

    Reviewpatients with metabolic syndrome and related disordersn = 1,890

    The Effects of Curcumin on Glycemic Control and Lipid Profiles Among Patients with Metabolic Syndrome and Related Disorders: A Systematic Review and Metaanalysis of Randomized Controlled Trials

    Current pharmaceutical design

More on LDL cholesterol

Flow-mediated dilation

upin humans5no changein humans2

7 studies
  1. Curcumin showed no clear effect on flow-mediated dilation in humans (stage 3b or 4 CKD) (median change from baseline was -0.7 (-2.1, 1.1) and -0.1 (-1.5, 1.5) for curcumin and placebo, respectively, with p = 0.69).

    “Compared with placebo, 12 months of curcumin did not improve FMD”

    Human trialstage 3b or 4 CKDLongvida®2000 mg/day12 monthsn = 88

    Curcumin Supplementation and Vascular and Cognitive Function in Chronic Kidney Disease: A Randomized Controlled Trial

    Antioxidants (Basel, Switzerland)

  2. Curcumin showed no clear effect on flow-mediated dilation in humans (coupled with oral nutritional supplement).

    “Brachial artery flow-mediated dilation and middle cerebral artery blood flow were unchanged in both conditions (p > 0.05).”

    Human trialcoupled with oral nutritional supplement1000 mgacuten = 12

    Curcumin Enhances Fed-State Muscle Microvascular Perfusion but Not Leg Glucose Uptake in Older Adults

    Nutrients

  3. Curcumin increases flow-mediated dilation in humans.

    “Flow-mediated dilation increased significantly and equally in the curcumin and exercise groups”

    Human trialorally8 weeksfemales

    Curcumin ingestion and exercise training improve vascular endothelial function in postmenopausal women

    Nutrition research (New York, N.Y.)

  4. Curcumin improves flow-mediated dilation in humans (metabolic disorders) (WMD = 1.64, 95 % CI: 1.06, 2.22).

    “increased flow-mediated dilation (FMD) [WMD = 1.64, 95 % CI: 1.06, 2.22; p < 0.001”

    Reviewmetabolic disorders

    The effect of curcumin supplementation on endothelial function and blood pressure in patients with metabolic disorders: A meta-analysis of meta-analyses

    Prostaglandins & other lipid mediators

  5. Curcumin increases flow-mediated dilation in humans (WMD = 1.64, 95% CI: 1.06 to 2.22).

    “increased flow-mediated dilation (FMD) (WMD = 1.64, 95 % CI: 1.06, 2.22, P < 0.001)”

    Review

    The effects of curcumin supplementation on biomarkers of inflammation, oxidative stress, and endothelial function: A meta-analysis of meta-analyses

    Prostaglandins & other lipid mediators

  6. Curcumin increases flow-mediated dilation in humans (compared to the control group) (overall ES 1.379 (95% CI 0.485-2.274, p = 0.003)).

    “supplementation with curcumin preparations had an overall ES (standard difference in means) of 1.379 (95% CI 0.485-2.274, p = 0.003) on FMD.”

    Reviewcompared to the control group

    Curcumin Preparations Can Improve Flow-Mediated Dilation and Endothelial Function: A Meta-Analysis

    Complementary medicine research

  7. Curcumin increases flow-mediated dilation in humans (WMD: 1.49; 95% CI [0.16, 2.82]).

    “We found a significant increase in flow-mediated dilation (FMD) following curcumin supplementation (WMD: 1.49; 95% CI [0.16, 2.82]).”

    Review

    The effects of curcumin supplementation on endothelial function: A systematic review and meta-analysis of randomized controlled trials

    Phytotherapy research : PTR

More on Flow-mediated dilation

IL-6

downin humans3no changein humans3downin human cells1

7 studies
  1. Curcumin decreases IL-6 in humans.

    “However, between-group comparisons revealed that 12-month curcumin supplementation reduced IL-6 more than placebo.”

    Human trial12 monthsn = 88

    Curcumin Supplementation and Vascular and Cognitive Function in Chronic Kidney Disease: A Randomized Controlled Trial

    Antioxidants (Basel, Switzerland)

  2. Curcumin showed no clear effect on IL-6 in obese individuals; same null result for IL-2, IL-8, IL-10, IFN-γ, EGF and MCP-1.

    “no significant difference was observed in the concentrations of IL-2, IL-6, IL-8, IL-10, IFNγ, EGF, and MCP-1”

    Human trialin obese individuals; same null result for IL-2, IL-8, IL-10, IFN-γ, EGF and MCP-11 g daily4 weeksn = 30

    Investigation of the effects of curcumin on serum cytokines in obese individuals: a randomized controlled trial

    TheScientificWorldJournal

  3. Curcumin decreases IL-6 in humans (hemodialysis) (SMD -0.4, 95% CI -0.8 to -0.07).

    “interlukine-6 (IL-6) levels (SMD: -0.4; 95% CI: -0.8 to -0.07; p = 0.02, I2 = 31.6%, 3 studies, 153 participants) compared control group”

    Reviewhemodialysisn = 153

    The effects of curcumin-containing supplements on inflammatory biomarkers in hemodialysis patients: A systematic review and meta-analysis

    Phytotherapy research : PTR

  4. Curcumin showed no clear effect on IL-6 in patients with an inflammatory background (WMD = -0.33 pg/ml, 95% CI = -0.99-0.34, P = 0.33).

    “curcumin/turmeric supplementation was non-significantly associated with reduced levels of IL-6 (WMD = -0.33 pg/ml, 95% CI = -0.99-0.34, P = 0.33)”

    Reviewin patients with an inflammatory backgroundserum

    Effect of curcumin on proinflammatory cytokines: A meta-analysis of randomized controlled trials

    Cytokine

  5. Curcumin showed no clear effect on IL-6 in humans (chronic inflammatory diseases) (MD -0.71 pg/mL, 95%CI -1.68 to 0.25, p = 0.15).

    “IL-6 (MD -0.71 pg/mL, 95%CI -1.68 to 0.25, p = 0.15)”

    Reviewchronic inflammatory diseasesoral4 and 16 weeks

    Oral turmeric/curcumin effects on inflammatory markers in chronic inflammatory diseases: A systematic review and meta-analysis of randomized controlled trials

    Pharmacological research

  6. Curcumin decreases IL-6 in RS-like cells.

    “Furthermore, NF-κB inhibitors, JSH-23 and curcumin reduced IL-6 secretion from RS-like cells.”

    Cellsin RS-like cells

    Reed-Sternberg cells in Hodgkin's lymphoma present features of cellular senescence

    Cell death & disease

  7. Curcumin decreases IL-6 in humans (WMD: -0.60pg/mL, 95% CI: -1.06, -0.14, p=0.011).

    “There was a significant reduction of circulating IL-6 concentrations following curcuminoids supplementation (WMD: -0.60pg/mL, 95% CI: -1.06, -0.14, p=0.011).”

    Review

    Effect of curcumin on circulating interleukin-6 concentrations: A systematic review and meta-analysis of randomized controlled trials

    Pharmacological research

More on IL-6

All 332

What is curcumin linked with?

14

Studies link curcumin with 14 measures, among them microbiome composition, atrial fibrillation and metabolic syndrome.

Microbiome composition

mixedin humans2

2 studies
  1. Curcumin is associated with microbiome composition in humans (prediabetes or overweight/obesity).

    “Gut microbiome analysis revealed no significant changes in alpha diversity or beta diversity of microbiome; however, there was marginal enrichment of beneficial bacteria”

    Human trialprediabetes or overweight/obesitycapsules80 mg12 weeksn = 23

    Twelve-Week Curcumin Supplementation Improves Glucose Homeostasis and Gut Health in Prediabetic Older Adults: A Pilot, Double-Blind, Placebo-Controlled Trial

    Nutrients

  2. Curcumin is associated with microbiome composition in humans (chronic kidney disease).

    “Regarding GM, after 6 months of curcumin supplementation, Escherichia-Shigella was significantly lower, while Lachnoclostridium was significant higher.”

    Human trialchronic kidney disease6 monthsn = 24

    Curcumin Supplementation (Meriva®) Modulates Inflammation, Lipid Peroxidation and Gut Microbiota Composition in Chronic Kidney Disease

    Nutrients

More on Microbiome composition

Atrial fibrillation

downin mice2

2 studies
  1. Curcumin lowers the risk of atrial fibrillation in mice (aged mice).

    “curcumin reduced the susceptibility AF of aged mice by improving aging-related atrial fibrosis”

    Animalsaged miceatrium100 mg/kg

    Curcumin improves atrial fibrillation susceptibility by regulating tsRNA expression in aging mouse atrium

    PeerJ

  2. Curcumin lowers the risk of atrial fibrillation in mice (aging).

    “p300 inhibitor curcumin and p300 knockdown treated aging mouse and senescence human atrial fibroblasts reduced the senescence ratio of atrial fibroblasts, ameliorated the atrial fibrosis, and decreased the AF inducibility”

    Animalsaging

    Acetyltransferase p300 regulates atrial fibroblast senescence and age-related atrial fibrosis through p53/Smad3 axis

    Aging cell

More on Atrial fibrillation

Metabolic syndrome

downin humans1

1 study
  1. Curcumin lowers the risk of metabolic syndrome in humans.

    “The frequency of patients with fatty liver and metabolic syndrome at the end of the intervention was significantly lower in the curcumin group than in the control group.”

    Human trial12 weeks

    Curcumin Offers No Additional Benefit to Lifestyle Intervention on Cardiometabolic Status in Patients with Non-Alcoholic Fatty Liver Disease

    Nutrients

  2. Curcumin lowers the risk of metabolic syndrome in humans with lifestyle modification (p = 0.012).

    “After the intervention, there was a lower number of patients with severe fatty liver (FLI ≥ 60) and metabolic syndrome in the curcumin group compared to the placebo (p = 0.021 and p = 0.012, respectively).”

    Human trialwith lifestyle modification12 weeks

    Curcumin Offers No Additional Benefit to Lifestyle Intervention on Cardiometabolic Status in Patients with Non-Alcoholic Fatty Liver Disease

    Nutrients

More on Metabolic syndrome

Breast and prostate cancer

downin reviews1

1 study
  1. Curcumin lowers the risk of breast and prostate cancer.

    “bioactive compounds, especially curcumin in turmeric and isoflavones in soybean, contribute to decreased risk of certain cancers, such as breast and prostate cancer”

    Review

    The Role of Nutritional Foods in the Prevention of Chronic Diseases: A Comprehensive Review

    Ecology Environment and Conservation

More on Breast and prostate cancer

Atherosclerotic cardiovascular disease

downin humans1

1 study
  1. Curcumin lowers the risk of atherosclerotic cardiovascular disease in humans with diabetes and atherosclerotic cardiovascular risk.

    “Upon assessing the (ASCVD) risk class distribution between the two groups, a significant difference was noted at the end of the trial (P = 0.004).”

    Human trialwith diabetes and atherosclerotic cardiovascular risk14 weeksn = 72

    Curcumin supplementation improves the clinical outcomes of patients with diabetes and atherosclerotic cardiovascular risk

    Scientific reports

More on Atherosclerotic cardiovascular disease

MSRA

upin zebrafish cells1

1 study
  1. Curcumin is associated with MSRA in cells.

    “Curcumin's antiaging effects were found to be linked to MsrA-mediated redox pathways for the first time.”

    Cellsin cells

    Novel Visual Perspective for Tracking of Larval Development, Aging and Antiaging Drugs Screening by Fluorescent Sensing MsrA

    Analytical chemistry

More on MSRA

Neurodegenerative disease

downin humans1

1 study
  1. Curcumin is associated with neurodegenerative disease in humans.

    “the incidence of neurodegenerative diseases is low in societies that consume curcumin widely”

    Review

    Relationship of Curcumin with Aging and Alzheimer and Parkinson Disease, the Most Prevalent Age-Related Neurodegenerative Diseases: A Narrative Review

    Nutrition reviews

More on Neurodegenerative disease

Dasatinib

no changein silico1

1 study
  1. Curcumin is associated with dasatinib in silico (based on similarity in gene expression effects).

    “The natural senolytic piperlongumine (a compound found in long pepper), and the natural senomorphics parthenolide, phloretin and curcumin (found in various edible plants) were identified as potential substitutes of dasatinib.”

    In silicobased on similarity in gene expression effects

    Computational identification of natural senotherapeutic compounds that mimic dasatinib based on gene expression data

    Scientific reports

More on Dasatinib

Inflammatory biomarkers

mixedin humans1

1 study
  1. Curcumin is associated with inflammatory biomarkers in humans (Compared with placebo in older adults with low-grade systemic inflammation) (Galectin-3 d=-0.31 (larger decrease); interleukin-6 d=0.38 (smaller increase)).

    “Effect sizes for galectin-3 (d=-0.31) (larger decrease) and interleukin-6 (d=0.38) (smaller increase) were small in the Curcumin C3 Complex® group compared to placebo.”

    Human trialCompared with placebo in older adults with low-grade systemic inflammationCurcumin C3 Complex®1000mg/day12 weeks8 females and 9 malessn = 17

    Effects of Curcumin C3 Complex® on Physical Function in Moderately Functioning Older Adults with Low-Grade Inflammation - A Pilot Trial

    The Journal of frailty & aging

More on Inflammatory biomarkers

Cognitive function

mixedin humans1

1 study
  1. Curcumin is associated with cognitive function in humans.

    “resulting in mixed and inconclusive findings”

    Review

    Curcuma Longa, the "Golden Spice" to Counteract Neuroinflammaging and Cognitive Decline-What Have We Learned and What Needs to Be Done

    Nutrients

All 14

Has curcumin been tested in people?

1 of 110 about aging

Yes: 201 trials and 6 observational studies in people have been published, and 110 trials are registered.

Every condition in trials

40 of 93

Stopped

  • NCT00852332TerminatedBreast neoplasm

    The trial was stopped for futility in view of the results of the anticipated analysis

  • NCT02944578TerminatedTumor

    Study was terminated due to patient feedback and need to redesign the delivery method.

  • NCT00745134TerminatedRectal neoplasms

    The trial was stopped early because there was only one patient with pCR among the first 15 patients randomized to the curcumin arm.

  • NCT01928043TerminatedBipolar disorder

    insufficient recruitment

  • NCT03953261TerminatedSystemic lupus erythematosus

    COVID and lack of support staff 2. lack of support staff to conduct the study

  • NCT02300727TerminatedMucositis

    Protocol failed to accrue sufficient subject to complete meaningful analysis.

Trial sponsors

Funding

5 grants since 2018

National Heart, Lung, and Blood Institute$1.7MSão Paulo Research FoundationJapan Society for the Promotion of Science¥4.7M

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    Independent labs report that curcumin extends lifespan in T. castaneum, shortens it in worms at 10 µM, and reduces human inflammation. Other studies report worm lifespan extension, unchanged mouse lifespan or unchanged human inflammation. One registered trial concerns aging; 32 trials across uses ended over a year ago without posted results or citing papers, and some papers declare company ties.

  2. Summary rewritten as its findings changed.

    As it read before

    Curcumin extends lifespan in worms and T. castaneum, independently replicated in the latter, while mouse lifespan results differ. Independent labs report reduced human inflammation, alongside null results. None of its registered trials is classified as aging-focused; 37 ended over a year ago without posted results or linked papers, and some papers have company authors or disclose company ties.

  3. Summary rewritten as its findings changed.

    As it read before

    A human trial shows curcumin lowers HbA1c in prediabetes, and a worm study reports more moving worms. One mouse study finds reduced weight gain, hypertension and hypothalamic pNMDAR in ovariectomized, high-fat-fed females, but unchanged pNMDAR in lean or obese males.

  4. Summary written from the findings.

Latest

Dec 2025: 6Jan 2026: 25Feb 2026: 7Mar 2026: 8Apr 2026: 7May 2026: 9Jun 2026: 8Jul 2026: 13Aug 2026: 13Sep 2026: 4Oct 2026: 9Nov 2026: 3112 papers in 12 months
European Journal of Public Health

Food colorings linked to higher cardiovascular disease risk

The highest versus lowest intake group had hazard ratios of 1.36 for high blood pressure and 1.18 for cardiovascular disease.The highest versus lowest intake group had hazard ratios of 1.36 for high blood pressure and 1.18 for cardiovascular disease.

Cohort · 112,395 peopleCardiovascular disease

See all 566 papers on curcumin